Regulatory Validation European regulatory clearance and clinical data show that VGS products reduce vein graft disease and enhance graft longevity, creating a strong entry point for hospitals and vascular centers in Europe.

Target Customers Key buyers include vascular surgeons, interventional radiologists, and dialysis programs that perform bypass grafts and AV fistula interventions, with VEST and FRAME FR addressing durability and stability.

Clinical Evidence Randomized trials and real-world European data demonstrate biomechanical benefits and improved outcomes, enabling compelling discussions on value and ROI with procurement teams.

Partnership Potential As a small, highly specialized company, VGS can scale through partnerships with large vascular device firms or regional distributors to broaden geographic reach and accelerate adoption.

Growth Opportunities There is potential to expand indications and regulatory footprint beyond current products, leveraging ongoing clinical work to open new sales lanes in bypass and dialysis related applications.